Literature DB >> 27823570

Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease.

Danielle A Simmons1, Frank M Longo1, Stephen M Massa2.   

Abstract

Effective non-genetic disease modifying treatments for Huntington's disease (HD) will necessarily target multiple diverse neurodegenerative processes triggered by mutant huntingtin. Neurotrophin receptors are well-positioned for this task as they regulate signaling pathways that largely overlap with signaling networks contributing to HD-related synaptic dysfunction, glial activation, excitotoxicity, and other degenerative processes. This review will discuss the contributions of disrupted neurotrophin receptor-related signaling to primary HD neuropathologies, and prospects for harnessing this signaling to develop therapeutics to counteract HD degenerative mechanisms. Application of the native protein ligands has been challenging pharmacologically, but progress has been made with the advent of small molecule compounds that can selectively bind to and activate specific Trk receptors or p75NTR to promote trophic and/or inhibit degenerative signaling in cell populations preferentially affected in HD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27823570     DOI: 10.2174/1871527315666161107093047

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  6 in total

1.  Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.

Authors:  Chelsy R Eddings; Nicolas Arbez; Sergey Akimov; Michal Geva; Michael R Hayden; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2019-05-17       Impact factor: 5.996

Review 2.  Molecular Pathophysiological Mechanisms in Huntington's Disease.

Authors:  Anamaria Jurcau
Journal:  Biomedicines       Date:  2022-06-17

3.  Differential regulation of Kidins220 isoforms in Huntington's disease.

Authors:  Álvaro Sebastián-Serrano; Ana Simón-García; Alicia Belmonte-Alfaro; Julia Pose-Utrilla; María Santos-Galindo; Ana Del Puerto; Lucía García-Guerra; Ivó H Hernández; Giampietro Schiavo; Miguel R Campanero; José J Lucas; Teresa Iglesias
Journal:  Brain Pathol       Date:  2019-07-16       Impact factor: 7.611

Review 4.  Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.

Authors:  Danielle A Simmons
Journal:  J Huntingtons Dis       Date:  2017

5.  Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31.

Authors:  Danielle A Simmons; Brian D Mills; Robert R Butler Iii; Jason Kuan; Tyne L M McHugh; Carolyn Akers; James Zhou; Wassim Syriani; Maged Grouban; Michael Zeineh; Frank M Longo
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

Review 6.  Neurotrophin gene therapy to promote survival of spiral ganglion neurons after deafness.

Authors:  Patricia A Leake; Omar Akil; Hainan Lang
Journal:  Hear Res       Date:  2020-04-05       Impact factor: 3.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.